Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) closed the day trading at $22.67 down -0.18% from the previous closing price of $22.71. In other words, the price has decreased by -$0.18 from its previous closing price. On the day, 1.28 million shares were traded. CNTA stock price reached its highest trading level at $23.24 during the session, while it also had its lowest trading level at $22.52.
Ratios:
For a better understanding of CNTA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.12 and its Current Ratio is at 10.12. In the meantime, Its Debt-to-Equity ratio is 0.34 whereas as Long-Term Debt/Eq ratio is at 0.34.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on September 03, 2025, initiated with a Overweight rating and assigned the stock a target price of $31.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 10 ’25 when Bush Tia L sold 25,000 shares for $22.00 per share. The transaction valued at 550,000 led to the insider holds 121,503 shares of the business.
Bush Tia L sold 24,792 shares of CNTA for $495,840 on Sep 09 ’25. The Chief Technology & Quality Ofc now owns 121,503 shares after completing the transaction at $20.00 per share. On Sep 10 ’25, another insider, HUSSAIN IQBAL J, who serves as the General Counsel of the company, sold 20,000 shares for $22.00 each. As a result, the insider received 440,000 and left with 105,386 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CNTA now has a Market Capitalization of 3044807680 and an Enterprise Value of 2912224768. For the stock, the TTM Price-to-Sale (P/S) ratio is 201.58 while its Price-to-Book (P/B) ratio in mrq is 8.80. Its current Enterprise Value per Revenue stands at 194.148 whereas that against EBITDA is -14.13.
Stock Price History:
The Beta on a monthly basis for CNTA is 1.49, which has changed by 0.33431435 over the last 52 weeks, in comparison to a change of 0.17089343 over the same period for the S&P500. Over the past 52 weeks, CNTA has reached a high of $22.95, while it has fallen to a 52-week low of $9.60. The 50-Day Moving Average of the stock is 37.22%, while the 200-Day Moving Average is calculated to be 47.59%.
Shares Statistics:
Over the past 3-months, CNTA traded about 1.21M shares per day on average, while over the past 10 days, CNTA traded about 1896730 shares per day. A total of 133.91M shares are outstanding, with a floating share count of 85.14M. Insiders hold about 36.42% of the company’s shares, while institutions hold 56.11% stake in the company. Shares short for CNTA as of 1756425600 were 5268748 with a Short Ratio of 4.36, compared to 1753920000 on 4362489. Therefore, it implies a Short% of Shares Outstanding of 5268748 and a Short% of Float of 4.63.
Earnings Estimates
The current rating of Centessa Pharmaceuticals plc ADR (CNTA) is the result of assessments by 8.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.43, with high estimates of -$0.38 and low estimates of -$0.51.
Analysts are recommending an EPS of between -$1.29 and -$1.46 for the fiscal current year, implying an average EPS of -$1.37. EPS for the following year is -$1.64, with 9.0 analysts recommending between -$1.37 and -$2.03.
